Valuation: Penumbra, Inc.

Market Cap 12.77B 11.06B 10.31B 9.48B 17.9B 1,214B 18.1B 121B 47.55B 608B 47.96B 46.91B 2,012B P/E 2026 *
80.1x
P/E 2027 * 52.9x
Enterprise Value 12.23B 10.59B 9.88B 9.08B 17.15B 1,163B 17.34B 116B 45.55B 582B 45.94B 44.93B 1,928B EV / Sales 2026 *
7.67x
EV / Sales 2027 * 6.69x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week+0.77%
Current month+0.43%
1 month+1.37%
3 months-0.40%
6 months-5.68%
Current year+3.75%
1 week 318.54
Extreme 318.54
324.35
1 month 315.69
Extreme 315.69
324.35
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
2/13/26 Free

Founder

589 0.0015%
2/13/26 Free

Director

589 0.0015%
2/13/26 Free

General Counsel

5,742 0.0146%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%+0.77%+34.35%+27.67% 12.77B
-0.58%+0.13%+23.91%+23.33% 6.84B
+1.17%+1.90%+54.12%+28.42% 6.06B
-2.63%-0.27% - - 5.33B
-0.48%+0.91%-23.60%+39.21% 4.52B
-0.86%+2.49%-21.68%-19.05% 4.11B
-1.38%+5.20%+39.90%-40.60% 1.89B
0.00%+0.85%-11.46%+205.13% 1.77B
+1.78%+2.27%+62.37%-2.63% 1.63B
0.00%+5.93%-30.55%-49.27% 1.28B
Average -0.46%+1.44%+14.15%+23.58% 4.62B
Weighted average by Cap. -0.59%+1.49%+20.85%+24.51%

Financials

2026 *2027 *
Net sales 1.6B 1.38B 1.29B 1.18B 2.24B 152B 2.26B 15.14B 5.94B 75.9B 5.99B 5.86B 251B 1.8B 1.56B 1.45B 1.34B 2.52B 171B 2.55B 17.08B 6.7B 85.63B 6.76B 6.61B 284B
Net income 171M 148M 138M 127M 239M 16.23B 242M 1.62B 635M 8.12B 641M 627M 26.89B 242M 210M 196M 180M 340M 23.04B 343M 2.3B 902M 11.53B 910M 890M 38.18B
Net Debt -538M -466M -434M -399M -754M -51.14B -762M -5.1B -2B -25.59B -2.02B -1.98B -84.75B -729M -631M -588M -541M -1.02B -69.29B -1.03B -6.91B -2.71B -34.67B -2.74B -2.68B -115B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-08-05 US$322.71 -0.47% 147,892
26-08-04 US$324.22 +0.37% 363,249
26-08-03 US$323.02 +0.57% 328,452
26-07-31 US$321.19 +0.43% 295,954
26-07-30 US$319.83 -0.09% 357,943
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
324.22USD
Average target price
361.83USD
Spread / Average Target
+11.60%

Quarterly revenue - Rate of surprise